Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Endothelin A Receptor (ETAR)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_616

Synonyms

Historical Background

Endothelin-1 (ET-1) is a 21-amino-acid vasoactive peptide (see structure in Table 1) that was first isolated and identified in 1988 from porcine aortic endothelial cells. The endothelin family consists of three isoforms: ET-1, ET-2, and ET-3. ET-1 is the principal isoform and is a very potent vasoconstrictor and growth promoter. The physiological effects of the ET system are many and include regulation of vascular tone, renal function, and cell proliferation. ET exerts its effects through two types of endothelin receptors: type A (ETAR) and type B (ETBR). ETAR and ETBR are G-protein-coupled receptors (GPCRs) that share homology with the rhodopsin family. ETAR is pharmacologically distinguished from ETBR by ligand selectivity to the ET isoforms and cardiotoxic peptides isolated from snake venoms sarafotoxins 6b and 6c (S6b, S6c). ETAR binds ET-1 and ET-2 isoforms with much greater affinity than ET-3 (ET-1 = ET-2 > S6b > ET-3), while ETBR binds ET-3 and the venoms S6b and S6c with the same affinity as ET-1 and ET-2 (ET-1 = ET-2 = ET-3). A third receptor subtype specific for ET-3, termed the endothelin C receptor (ETCR), has been cloned and characterized from Xenopus laevis but is absent in mammalian species (Barton and Yanagisawa 2008; Davenport 2002).
Endothelin A Receptor (ETAR), Table 1

Endothelin A Receptor (ETAR), Table 1 Agonists and antagonists acting at ETAR

ETAR is expressed in many tissues and organs. It is the principal receptor subtype in the cardiovascular system mediating vasoconstriction, vascular cell proliferation, and the hypertrophic effects and positive inotropic effects of ET-1 in cardiac myocytes. In contrast, ETBR is the predominant receptor on endothelial cells and its activation opposes many of the effects mediated by ETAR stimulation; thus ETBR stimulation results in vasodilation (NO and prostacyclin release from endothelial cells), natriuresis, and clearance of ET-1 from the circulation. Endothelin binds irreversibly to ETAR and, depending on cell type, couples to multiple G proteins (Gq/11, Gi, G12/13) activating a network of signaling pathways. Activation of ETAR is important in wound healing and is implicated in many of the pathophysiological effects of ET-1, including cardiovascular disease, pulmonary and systemic hypertension, atherosclerosis, fibrotic diseases, renal disease, diabetes, cancer, inflammation, pain, and hyperalgesia (Schneider et al. 2007; Barton and Yanagisawa 2008; Khimji and Rockey 2010; Bagnato et al. 2011).

Localization of the ETA Receptor

ETAR is the predominant subtype expressed in vascular smooth muscle cells and cardiac myocytes, but is absent in endothelial cells. ETAR is present in cells and tissues of the lungs, kidneys, liver, CNS, adrenal glands, eyes, and ovaries. Confocal microscopy and immunohistochemical analysis demonstrate that ETAR is largely localized on cell surface on plasma membranes, and the cytoplasmic tail of ETAR is important for proper localization. In cardiac myocytes, ETAR is present on the sarcolemma, transverse-tubules and, when internalized, is located in the nuclear envelope of ventricular myocytes (Kuc et al. 2006; Bkaily et al. 2011; Hilal-Dandan and Brunton 2010).

ETAR-Activated Signaling Pathways

ET-1 stimulation of ETAR may induce a variety of physiological responses, depending on the differentiated properties of the target cells. ETAR can couple to multiple G proteins, principally Gq, Gi, and likely G12 to modulate a large array of signaling pathways (Hilal-Dandan et al. 1997; Takigawa et al. 1995; Ivey et al. 2008). Takigawa et al. (1995) co-expressed ETAR with different G-protein a subunits in COS-7 cells and found that ETAR coupled to Gq/11, G12/13, and Gs. There are a few reports of physiological coupling of ETAR activation to elevation of cyclic AMP, but this is likely not direct but mediated by paracrine mechanisms such as ET-stimulated eicosanoid production (Ivey et al. 2008).

Vasoconstrictor and growth-promoting effects of ET-1, mediated via Gq, result in the activation of phospholipase C-ß and generation of inositol triphosphate (IP3) and diacylglycerol. These molecules induce Ca++ release and activate protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and small G proteins (Ivey et al. 2008; Rosano et al. 2009; Khimji and Rockey 2010). In smooth muscle, IP3 induces Ca++ release from the sarcoplasmic reticulum, triggering further elevation of intracellular Ca++ and contraction. Cell growth and proliferation are induced through coupling to Gq signaling; Gi and G12 signaling can also regulate activation of MAPKs and induction of immediate early genes (Fig. 1). For example, in cardiac myocytes, coupling of ETAR to Gq and pertussis-sensitive Gi pathways contribute to the hypertrophic response (Hilal-Dandan et al. 1997). ETAR mediates the activation of  phospholipase D (PLD), phospholipase A2 (PLA2), and the release of arachidonic acid and production of prostaglandins. Depending on the cell type, ETAR may couple to Gi to inhibit  adenylyl cyclase activity, resulting in a decrease in cyclic AMP production. Signaling through ETAR also induces activation of Rho, Ras, Rac, MAPK, JNK, p38 MAPK, PI-3-K-dependent Akt activation, and stimulation of several protein tyrosine kinases. The effects vary with the cell type and may contribute to inflammation, cell growth, survival and proliferation, cell invasion and migration, and inflammation (Ivey et al. 2008; Rosano et al. 2009). The mitogenic effects of ET-1, mediated through ETAR, may be amplified by cross talk and activation of EGFR. Stimulated ETAR can induce translocation of ß-arrestin to the plasma membrane to form ETAR/ß-arrestin complex. ß-arrestin acts as a scaffold that recruits intracellular signaling molecules. The ETAR/ß-arrestin complex interacts with c-  Src to stimulate transactivation of EGFR and tyrosine phosphorylation of ß-catenin, and with axin (a negative regulator of the Wnt signaling pathway) to inactivate glycogen synthase kinase (GSK)-3ß and stabilize  ß-catenin. The pathways that link ETAR with ß-catenin induce Ras-dependent MAPK activation and are associated with cell migration and plaque formation in atherosclerosis, as well as the progression and invasiveness of ovarian cancer (Rosano et al. 2009).
Endothelin A Receptor (ETAR), Fig. 1

ET-1 signaling via the ETAR. ETAR couples principally to Gq and Gi, with coupling to G12 also possible. Cellular responses are complex due to multiplicity of G protein coupling in a single cell, cross talk amongst pathways, transactivation of the EGFR, and influence of paracrine signaling in response to activation of phospholipases and subsequent eicosanoid production

Ligand Binding, Internalization, and Regulation of Activity

Human ETAR is located on chromosome 4, is 427 amino acids long, and shares ∼60% sequence homology with ETBR. The intracellular third loop and carboxyl-terminal domains are required for binding and signaling. Based on chimeric experiments between human ETAR and ETBR, the transmembrane (TM) helices 4–6 seem to determine isoform selectivity, whereas portions of TM 1–3 and 7 plus adjacent extracellular loop regions bind the ETAR-selective antagonist BQ-123 (reviewed by Davenport 2002; Hilal-Dandan and Brunton 2010). The selectivity of ETAR binding to ET isoforms and the snake venoms S6b and S6c pharmacologically distinguishes ETAR from the nonselective ETBR. The order of potency for ETAR binding and activation is ET-1 = ET-2 > S6b > ET-3; S6c is inactive (Hilal-Dandan et al. 1997). Numerous ETAR-selective and nonselective antagonists have been developed, including both peptide and non-peptide ligands (see Table 1).

The binding of ET-1 to ETAR is quasi-irreversible and the primary effects on Gq and Gi pathways are sustained and cannot by removed by washing cells exposed to ET-1 (Hilal-Dandan et al. 1997). Thus, attempts to reverse ET-1 action at ETAR using competitive inhibitors are not successful, whereas simultaneous addition of receptor antagonists and ET-1 is effective at reducing ET-1’s subsequent effects. Following ligand binding, conformational changes induce receptor internalization and recycling. Ligand-bound ETAR remains intact for up to 2 h following internalization, and maintains G-protein-coupled signaling. Internalization of ligand-bound ETAR follows the ß-arrestin–dynamin–caveolae and clathrin-coated pit pathways. The internalized receptors co-localize with transferrin and are recycled to the surface. Internalized ET-1/ETAR complexes can localize in perinuclear structures. The cytoplasmic C-terminal tail of ETAR determines its intracellular trafficking through a pericentriolar pathway for recycling. Truncation of the C-terminal tail causes ETAR to be directed toward lysosomal degradation (Paasche et al. 2005; Bkaily et al. 2011; see review Hilal-Dandan and Brunton 2010).

Modifications of ETAR include glycosylation, phosphorylation, and palmitoylation. Palmitoylation of the cysteine residues in the cytoplasmic tail modulates ETAR’s activity in coupling to Gq signaling, ERK activation, and Gi signaling, but has no effect on ligand binding. Homologous desensitization of ETAR can be induced by GRK2- and GRK3-mediated phosphorylation in vascular smooth muscle cells and cardiac myocytes; the specific residues that are phosphorylated have not been identified (for review see Hilal-Dandan and Brunton 2010).

ETAR can form homodimers or heterodimers with ETBR but the functional significance is not clear. ETAR–ETBR heterodimers in certain cell types have been reported to modify ligand binding and transmembrane signaling, which may explain nontypical receptor behavior. Pharmacologically, selective antagonists to both ETAR and ETBR may be required to inhibit the function of heterodimers (Evans and Walker 2008). For example, there is an increased sensitivity to the contractile actions of ET-1 in rat and human ischemic cerebral arteries following subarachnoid hemorrhage (Edvinsson and Povlsen 2011). In these ischemic arteries, ETBR but not ETAR is upregulated. While the ETBR agonist S6c does not elicit any contractile responses in these arteries, antagonists to ETBR attenuate ET-1-induced contraction; these results suggest possible interaction or dimerization between ETAR and ETBR that enhances sensitivity to ET-1 (Edvinsson and Povlsen 2011). ETAR can form a complex with ß-arrestin that interacts with c-Src to stimulate transactivation of EGFR (Rosano et al. 2009).

Genetic Variants

The human ETAR gene has eight exons and seven introns. Alternative mRNA transcripts of ETAR translate into truncated and nonfunctional receptors. Splice variants of ETAR isolated from human tissue include two alternative transcripts designated ETAR?4 and ETAR?3,4 (with deletions corresponding to exon 4 and exons 3 and 4, respectively) that result in nonfunctional receptors; a third mRNA transcript designated ETAR?3 (deletion corresponding to exon 3), identified in human placental tissue, results in a truncated and nonfunctional ETAR. The function of these splice variants is not clear and may involve regulation of ETAR expression and function (reviewed by Davenport 2002; Hilal-Dandan and Brunton 2010).

Genetically engineered homozygous ETAR knockout mice are not viable and resemble ET-1-knockout mice. ETAR/ mice have defects in cephalic neural crest cell derivatives. Abnormalities include craniofacial deformities, a poorly formed mandible, abnormal development of the middle ear structures, and tracheal narrowing. Cardiovascular defects include a defective aortic septum and defects in cardiac outflow tract with abnormalities in the aortic arch and great vessels. Signaling through ETAR is important for proper development of pharyngeal arches and aortic arch patterning. ET-1/ETAR signaling is responsible for a choice of morphogenetic program that determines maxillary and mandibular structures. The loss of ET-1/ETAR signaling affects homeotic genes, causing transformation of lower jaw into upper jaw structures, whereas constitutive activation of ETAR has the opposite effect, conversion of maxillary structures into mandibular structures (Sato et al. 2008).

ETAR in Disease

Signaling through ETAR is anti-apoptotic and induces cell growth, hypertrophy and proliferation, cell invasiveness and migration, fibrosis, and inflammation; thus, endothelin and the activation of ETAR are implicated in numerous pathological conditions.

Elevated tissue and plasma immunoreactive levels of ET-1 are associated with the severity and prognosis of congestive heart failure following myocardial infarction. In addition, upregulation of ETAR reportedly occurs in human and animal experimental models of heart failure (Schneider et al. 2007). In animal models, ETAR antagonists are beneficial in protecting against hypertensive heart failure and myocardial ischemia. Antagonism of ETA receptor reduces cardiac hypertrophy induced by aortic stenosis in rats and improves survival in rat models with chronic heart failure by improving cardiac output and decreasing left ventricular hypertrophy. In humans, however, clinical studies have been inconclusive with regard to any long-term advantages of ETAR blockade in treating patients with hypertension and heart failure (Schneider et al. 2007). On the other hand, ET-1 levels and ETAR are upregulated in experimental and human pulmonary arterial hypertension (PAH), and blockade of ETAR is clinically beneficial in reducing pulmonary arterial pressure and reversing arterial remodeling (Schneider et al. 2007; Abman 2009). Figure 2 shows the cell-cell and paracrine interactions involved in therapy of PAH and suggests how ETAR antagonists form one facet of a multi-agent approach. Bosentan and ambrisentan are currently approved for treatment of PAH in the USA (Motte et al. 2006; Abman 2009). Sitaxsentan, approved in Europe since 2006, was withdrawn in 2010 by Pfizer due to toxic liver damage.
Endothelin A Receptor (ETAR), Fig. 2

Rationale for use of ET-1 antagonists in treating PAH. (a) In healthy pulmonary artery, there is an appropriate balance between contractile/proliferative and relaxant/anti-proliferative influences. (b) In PAH, vascular tone is altered to favor contraction and proliferation. Excess ET-1 signaling via the ETAR receptor may be one of the pathogenic factors. (c) Pharmacotherapy to restore appropriate balance may include the use of ETAR antagonists such as ambrisentan (This diagram is reproduced with permission from Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th edition; see Barnes 2011. For details, consult the original reference)

Downregulation of ETAR may also occur as a consequence of elevated ET-1 plasma levels. Downregulation of ETAR in the heart, aorta, and pulmonary arteries is reported in hypertension induced by adenovirus-mediated gene transfer of ET-1, and in ETBR−/− deficient mice that have elevated circulating ET-1 levels due to reduced clearance by ETBR (Kuc et al. 2006). About 20–50% downregulation in ETAR levels has been observed in the aorta and pulmonary arteries of some human diseased hearts, and this has been suggested to be a compensation for elevated plasma ET-1 levels (Kuc et al. 2006).

Both ET-1 levels and ETAR are elevated in chronic kidney disease (CKD) and acute renal failure (Kohan 2010). The ET system is involved in regulation of renal blood flow, reabsorption of Na+ and water, cell proliferation, and extracellular matrix accumulation. Preclinical studies indicate that selective blockade of the ETAR increases renal blood flow and reduces proteinuria, blood pressure, and arterial stiffness in CKD (Dhaun et al. 2011). Increased ET-1 levels are reported in dysfunctional podocytes that will cause an increase in kidney damage and protein filtration. Blockade of ETAR reverses glomerulosclerosis and inhibits release of ET-1 and the shedding of podocyte-specific protein nephrin that is elevated in CKD. Clinical studies are currently assessing the long-term effects of ETAR blockade on morbidity and mortality of patients with CKD and diabetic nephropathy (Kohan 2010).

Upregulation of the ET system and activation of ETAR are associated with proliferation of VSMC. The mitogenic effects of ET-1 are amplified by synergistic interactions with growth factors such as epidermal growth factor (EFG), insulin, transforming growth factor-ß (TGF-ß), basic fibroblast growth factor (b- FGF), platelet-derived growth factor (PDGF), and release of cytokines, which contribute to the development of atherosclerotic plaques (Schneider et al. 2007; Ivey et al. 2008; Khimji and Rockey 2010). In animal models, ETAR blockade inhibits formation of atherosclerotic plaques and improves NO-mediated vasodilation (Barton and Yanagisawa 2008).

In many cancers, the ET system is upregulated and the levels correlate with the severity and progression of the disease (Bagnato et al. 2011). Increased expression of ET-1 and ETAR is associated with tumor growth and progression, neovascularizaion, and metastasis in several cancers including ovarian, prostate, breast, cervical, colon, and lung cancers (Bagnato et al. 2011). The mitogenic effects, mediated through ETAR, are enhanced by transactivation of the EGF receptor (EGFR) through activation of matrix-metalloproteinases (MMPs) that release precursor ligands of EGFR such as the heparin binding EGF-like growth factor (HB-EGF), or through direct phosphorylation by c-Src. Transactivation of EGFR potentiates cell proliferation, cell survival, and tumorigenesis by activating protein tyrosine kinases, PI3-kinase-dependent Akt activation, and Ras–MAPK pathways (Ivey et al. 2008; Rosano et al. 2009). ZD4054, an ETAR-specific antagonist, reportedly inhibits EGFR transactivation and metastasis and enhances tumor regression in ovarian cancer cell xenografts (Rosano et al. 2009). Also, silencing of ß-arrestins 1 and 2 prevents ETAR-induced Src activation, transactivation of EFGR, and metastasis (Rosano et al. 2009). Neovascularization and tumor progression correlate with vascular endothelial growth factor (VEGF) levels. ETAR stimulation enhances VEGF levels by increasing the protein levels of hypoxia-inducible factor 1a (HIF-1a) and increasing expression of cyclooxygenase (COX)-1 and COX-2 and the production of PGE2 (Bagnato et al. 2011). Clinical trials using the ETAR antagonist ZD4054 in patients with prostate cancer have reported improved overall survival (Bagnato et al. 2011). More studies are under way to evaluate the therapeutic value of ETAR antagonism in cancer treatment.

Injection of ET-1 in both human and animals induces spontaneous pain and hyperalgesia (increased sensitivity to pain). The nociceptive and hyperalgesic effects of ET-1 are predominantly mediated through ETAR activation, while ETBR may elicit either pain responses or analgesic effects through release of endorphins (Khodorova et al. 2009). The ETAR is localized on the cell bodies of small diameter sensory neurons of the dorsal root ganglia (DRG) which are associated with pain impulses. ETAR antagonists can ameliorate ET-1-induced acute pain in humans and animal models (Khodorova et al. 2009). Antagonists of ETAR are being tested for their potential analgesic effects in cancer-related pain (Bagnato et al. 2011).

Summary

Endothelin works through ETAR and ETBR to regulate multiple physiological events such as vascular tone, renal function, and cell growth and proliferation. Most of the studied pathophysiological effects of ET-1 are mediated through ETAR. Activation of ETAR is implicated in cardiac hypertrophy and congestive heart failure, ischemic heart disease, pulmonary and systemic hypertension, atherosclerosis, and renal disease. ETAR antagonists are being clinically evaluated in a number of diseases. Both ETAR-selective and nonselective blockers have proved to be beneficial and are currently in use for treatment of pulmonary hypertension. Given the significant pathophysiological role that has emerged of ET-1/ETAR activation in nociception, inflammation, and the progression and metastasis of many cancers, ETAR-selective blockade may provide a promising target of intervention in analgesia and cancer therapy.

References

  1. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med. 2009;60:13–23.PubMedCrossRefGoogle Scholar
  2. Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011;163:220–33.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Barnes PJ. Pulmonary pharmacology. In: Brunton L, Chabner B, Knollmann B, editors. The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 1031–66.Google Scholar
  4. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485–98.PubMedCrossRefGoogle Scholar
  5. Bkaily G, Avedanian L, Al-Khoury J, Provost C, Nader M, D'Orléans-Juste P, Jacques D. Nuclear membrane receptors for ET-1 in cardiovascular function. Am J Phys. 2011;300:R251–63.Google Scholar
  6. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219–26.PubMedCrossRefGoogle Scholar
  7. Dhaun N, Macintyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al. Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772–9.PubMedCrossRefGoogle Scholar
  8. Edvinsson L, Povlsen GK. Late cerebral ischaemia after subarachnoid haemorrhage: is cerebrovascular receptor upregulation the mechanism behind? Acta Physiol (Oxford). 2011;203:209–24.CrossRefGoogle Scholar
  9. Evans NJ, Walker JW. Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J. 2008;95:483–92.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Hilal-Dandan R, Brunton LL. Endothelin type A receptor. 2010. http://www.signaling-gateway.org/molecule/query?afcsid=A.000836. Accessed 30 Mar 2011.
  11. Hilal-Dandan R, Ramirez MT, Villegas S, Gonzalez A, Endo-Mochizuki Y, Brown JH, et al. Endothelin ETA receptor regulates signaling and ANF gene expression via multiple G protein-linked pathways. Am J Phys. 1997;272:H130–7.Google Scholar
  12. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis. 2008;199:237–47.PubMedCrossRefGoogle Scholar
  13. Khimji AK, Rockey DC. Endothelin – biology and disease. Cell Signal. 2010;22:1615–25.PubMedCrossRefGoogle Scholar
  14. Khodorova A, Montmayeur JP, Strichartz G. Endothelin receptors and pain. J Pain. 2009;10:4–28.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens. 2010;19:134–9.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Kuc RE, Maguire JJ, Davenport AP. Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice. Exp Biol Med (Maywood). 2006;231:741–5.Google Scholar
  17. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110:386–414.PubMedCrossRefGoogle Scholar
  18. Paasche JD, Attramadal T, Kristiansen K, Oksvold MP, Johansen HK, Huitfeldt HS, et al. Subtype-specific sorting of the ETA endothelin receptor by a novel endocytic recycling signal for G protein-coupled receptors. Mol Pharmacol. 2005;67:1581–90.PubMedCrossRefGoogle Scholar
  19. Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2009;106:2806–11.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Sato T, Kurihara Y, Asai R, Kawamura Y, Tonami K, Uchijima Y, et al. An endothelin-1 switch specifies maxillomandibular identity. Proc Natl Acad Sci U S A. 2008;105:18806–11.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47:731–59.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaki T, Goto K. Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors. Eur J Biochem. 1995;228:102–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.PharmacologyUniversity of California San DiegoSan DiegoUSA